Related references
Note: Only part of the references are listed.Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
Mai Tanaka et al.
CANCERS (2020)
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
Antonino Belfiore et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Michael D. Paul et al.
CHEMICAL REVIEWS (2019)
Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor
Binbin Zheng et al.
CHEMISTRY-AN ASIAN JOURNAL (2018)
SWISS-MODEL: homology modelling of protein structures and complexes
Andrew Waterhouse et al.
NUCLEIC ACIDS RESEARCH (2018)
Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
Shinji Nakamichi et al.
Oncotarget (2018)
Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety
Qidong Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
Jian-Zhong Lin et al.
ONCOTARGET (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation
Wei Yan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Reprogramming the immunological microenvironment through radiation and targeting Axl
Todd A. Aguilera et al.
NATURE COMMUNICATIONS (2016)
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3 beta/beta-catenin Signaling
Cun Wang et al.
THERANOSTICS (2016)
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
H. Yu et al.
BRITISH JOURNAL OF CANCER (2015)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Axl Activates Autocrine Transforming Growth Factor-β Signaling in Hepatocellular Carcinoma
Patrick Reichl et al.
HEPATOLOGY (2015)
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
Nitu Bansal et al.
ONCOTARGET (2015)
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).
Masamichi Mori et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan et al.
INVESTIGATIONAL NEW DRUGS (2013)
AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
Smita Salian-Mehta et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
Christopher D. Hart et al.
ONCOTARGETS AND THERAPY (2013)
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Christine Gjerdrum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target
Jan-Bart M. Koorstra et al.
CANCER BIOLOGY & THERAPY (2009)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Share Paper
